

WP2217617



Pfizer ApS
Lautrupvang 8
DK-2750 Ballerup
Tlf.: 44 20 11 00
Fax: 44 20 11 01
www.pfizer.dk
CVR.nr. 66351912

FAKS Foreningen af Kroniske Smertepatienter
Urtehaven 76, kld
2500 Valby
Att.: Pia Søndergaard Frederiksen

Ballerup 06 August 2019

Agreement on support to: FAKS Foreningen af Kroniske Smertepatienter Medlemsweekend 2019

Pfizer is very pleased to confirm that it will provide support to the above-mentioned project and has therefore entered into this Agreement.

The support will be given to FAKS Foreningen af Kroniske Smertepatienter (hereafter the Recipient).

The purpose of the activity is to support the important work for chronic pain patients with focus on quality of life.

The agreement shall run from 26 October to 27 October 2019.

Pfizer's financial commitment in relation to this Agreement shall be 25.000 DKK excl. VAT (not subject to VAT).

Pfizer will not provide any non-financial support.

The Recipient will ensure that the support is used solely for professional and scientific purposes in relation to this project and undertakes that any surplus from the support not used in accordance herewith will be refunded.

Upon request from Pfizer the Recipient must document that the support is spend in accordance with the above-mentioned.

The Recipient undertakes the full responsibility for the execution of this project and Pfizer disclaims every right to interfere with the execution and any other part of this project.
Furthermore the Recipient will be responsible for compliance with all applicable law.

Pfizer shall not be liable for damages of any kind and Pfizer provides no indemnification of any type.

Please complete and sign the attached Payment Form and return to Pfizer as soon as possible together with the signed agreement. Please note that Pfizer will be precluded from providing you with the financial support if you do not state a CVR-number on the Payment Form.

Disclosure

This agreement will be available on Pfizer's webpage (www.pfizer.dk) when the support is granted and for a period of 2 years thereafter.

WP2217617

Data Privacy

By signing this Agreement the Recipient agrees that Pfizer archives information about the Recipient and persons employed with the Recipient, who are or have been involved in this agreement. The Recipient carries the responsibility, that the persons who are involved in the agreement are informed and accept the processing and transfer of personal data., including name, contact details, and CVR-no in a global electronic system for processing of personal data. The electronic data processing system is accessible for a number of companies within the Pfizer group. The personal data can be transferred by Pfizer to other companies within the Pfizer group, to business partners as well as relevant governmental authorities, when this is necessary. Such recipients can be situated in countries outside the EC, e.g. the United States (so-called third-countries). For transfers from the EEA to countries not considered adequate by the European Commission, we have put in place adequate measures, such as by ensuring that the receiver is bound by EU Standard Contractual Clauses, to protect your personal data. By signing this Agreement the Recipient agrees that Pfizer may transfer such personal data to third countries in order to fulfil this Agreement and for the purpose of precise identification of Pfizer's business partners.

The Recipient is entitled to contact Pfizer, if the Recipient wishes to access the processed personal information about the Recipient. The Recipient is further entitled to have the relevant information changed or deleted. This applies for all persons mentioned in this section.


The support is provided under the provisions set forth in this agreement and in accordance with Pfizer's anti-corruption provisions (Appendix A).

By signing this agreement, the Recipient confirms to have read and understood Pfizer's policy relating to bribery and corruption pursuant to Appendix A and that the support is spend in accordance with the above mentioned terms and conditions.

We kindly ask you to return the signed agreement to Pfizer.


Date: august 9, 2019

Signature of authorized signatory on behalf of Pfizer:

DocuSigned by:

Troels Reiche
Medical Director

Date: August 12, 2019

Signature of authorized signatory on behalf of FAKS Foreningen af Kroniske Smertepatienter:

DocuSigned by:

Pia Søndergaard Frederiksen
Chairman of the Board for FAKS

Appendix A – Anti-Corruption Contract Provisions

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity and, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment; and
- 1.3 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support, has used or intend[s] to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.
- 1.4 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support.